Sun Yidi
School of Biomedical Engineering, Hainan University, Haikou, Hainan, China.
Front Genet. 2023 Apr 20;14:1183795. doi: 10.3389/fgene.2023.1183795. eCollection 2023.
It is now widely known that C-X3-C motif ligand 1 (CX3CL1) plays an essential part in the process of regulating pro-inflammatory cells migration across a wide range of inflammatory disorders, including a number of malignancies. However, there has been no comprehensive study on the correlation between CX3CL1 and cancers on the basis of clinical features. In order to investigate the potential function of CX3CL1 in the clinical prognosis and immunotherapy, I evaluated the expression of CX3CL1 in numerous cancer types, methylation levels and genetic alterations. I found CX3CL1 was differentially expressed in numerous cancer types, which indicated CX3CL1 may plays a potential role in tumor progression. Furthermore, CX3CL1 was variably expressed in methylation levels and gene alterations in most cancers according to The Cancer Genome Atlas (TCGA). CX3CL1 was robustly associated with clinical characteristics and pathological stages, suggesting that it was related to the degree of tumor malignancy and the physical function of patients. As determined by the Kaplan-Meier method of estimating survival, high CX3CL1 expression was associated with either favorable or unfavorable outcomes depending on the different types of cancer. It suggests the correlation between CX3CL1 and tumor prognosis. Significant positive correlations of CX3CL1 expression with CD4 T cells, M1 macrophage cells and activated mast cells have been established in the majority of TCGA malignancies. Which indicates CX3CL1 plays an important role in tumor immune microenvironment. Gene Ontology (GO) terms and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis suggested that the chemokine signaling pathway may shed light on the pathway for CX3CL1 to exert function. In a conclusion, our study comprehensively summarizes the potential role of CX3CL1 in clinical prognosis and immunotherapy, suggesting that CX3CL1 may represent a promising pharmacological treatment target of tumors.
目前广泛认为，C-X3-C基序配体1（CX3CL1）在调节促炎细胞跨多种炎症性疾病（包括多种恶性肿瘤）迁移的过程中起着至关重要的作用。然而，尚未有基于临床特征对CX3CL1与癌症之间相关性的全面研究。为了研究CX3CL1在临床预后和免疫治疗中的潜在作用，我评估了CX3CL1在多种癌症类型中的表达、甲基化水平和基因改变。我发现CX3CL1在多种癌症类型中差异表达，这表明CX3CL1可能在肿瘤进展中发挥潜在作用。此外，根据癌症基因组图谱（TCGA），CX3CL1在大多数癌症的甲基化水平和基因改变中表达各异。CX3CL1与临床特征和病理分期密切相关，表明它与肿瘤恶性程度和患者身体功能有关。通过Kaplan-Meier生存估计方法确定，根据不同癌症类型，CX3CL1高表达与有利或不利的预后相关。这表明CX3CL1与肿瘤预后之间存在相关性。在大多数TCGA恶性肿瘤中，已确定CX3CL1表达与CD4 T细胞、M1巨噬细胞和活化肥大细胞存在显著正相关。这表明CX3CL1在肿瘤免疫微环境中起重要作用。基因本体论（GO）术语和京都基因与基因组百科全书（KEGG）通路富集分析表明，趋化因子信号通路可能为CX3CL1发挥功能的途径提供线索。总之，我们的研究全面总结了CX3CL1在临床预后和免疫治疗中的潜在作用，表明CX3CL1可能是一种有前景的肿瘤药物治疗靶点。
